China-linked green group training US judges draws fresh heat as foreign ties fuel pressure at home

State Armor urges Congress to investigate the Environmental Law Institute over national security concerns stemming from ...

Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock

Protagonist Therapeutics (PTGX) exhibits strong technical momentum, posting a 150% gain over the past 52 weeks. PTGX holds a 100% “Buy” technical opinion from Barchart. Despite bullish analyst ...